Table. Serologic responses in 3 nonhuman primates sequentially vaccinated with 2 VSV-based VHF vaccines*.
| Nonhuman primate no. |
Lassa virus challenge study | Ebola virus challenge study |
| Prechallenge | Postchallenge | Prechallenge | Postchallenge | |||||
|---|---|---|---|---|---|---|---|---|
| LASV GPC |
LASV GPC |
LASV NP |
VSV |
EBOV GP |
EBOV GP |
EBOV VP40 |
VSV |
|
| 1 | ND | ND | 100 | 25,600 | 6,400 | 25,600 | 1,600 | 102,400 |
| 2 | ND | ND | <100 | 25,600 | 6,400 | 25,600 | 6,400 | 102,400 |
| 3 | ND | ND | <100 | 25,600 | 6,400 | 25,600 | 6,400 | 102,400 |
*VSV, vesicular stomatitis virus; VHF, viral hemorrhagic fever; LASV, Lassa virus; GPC, glycoprotein precursor; NP, nucleocapsid protein; EBOV, Ebola virus; GP, glycoprotein; VP40 viral protein 40; ND, not determined. Titers are indicated as reciprocal endpoint dilutions from ELISAs for recombinant antigens (LASV NP, EBOV GP, and VP40), or whole virus preparations (VSV).